Reaction
Oral Mucosal Exfoliation reporting signals
As of the last recalculation, Oral Mucosal Exfoliation appears in 1,496 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is ANAKINRA (PRR 92.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Anakinra | 103 | 92.7 | 93.3 |
| Bisacodyl Suppositories | 14 | 15.2 | 15.2 |
| Biscodyl | 14 | 15.0 | 15.1 |
| Hydroxychloroquine | 74 | 14.5 | 14.5 |
| Bisacodyl | 14 | 14.0 | 14.0 |
| Tocilizumab | 106 | 13.8 | 13.8 |
| Asenapine Maleate | 8 | 12.9 | 12.9 |
| Abatacept | 109 | 11.7 | 11.7 |
| Leflunomide | 81 | 11.3 | 11.3 |
| Fluticasone Furoate | 9 | 10.4 | 10.4 |
| Nicotine Polacrilex | 28 | 10.4 | 10.4 |
| Everolimus | 30 | 8.4 | 8.4 |
| Tofacitinib | 88 | 7.0 | 7.0 |
| Rucaparib | 4 | 6.3 | 6.3 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 10 | 5.8 | 5.8 |
| Bimekizumab | 8 | 5.2 | 5.2 |
| Pazopanib Hydrochloride | 9 | 4.6 | 4.7 |
| Cabozantinib | 13 | 3.8 | 3.8 |